SI2331098T1 - Postopki za dajanje iloperidona - Google Patents

Postopki za dajanje iloperidona

Info

Publication number
SI2331098T1
SI2331098T1 SI200931877T SI200931877T SI2331098T1 SI 2331098 T1 SI2331098 T1 SI 2331098T1 SI 200931877 T SI200931877 T SI 200931877T SI 200931877 T SI200931877 T SI 200931877T SI 2331098 T1 SI2331098 T1 SI 2331098T1
Authority
SI
Slovenia
Prior art keywords
iloperidone
administration
methods
Prior art date
Application number
SI200931877T
Other languages
English (en)
Slovenian (sl)
Inventor
Curt Wolfgang
Mihael Polymeropoulos
Christian Lavedan
Simona Volpi
Original Assignee
Vanda Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc. filed Critical Vanda Pharmaceuticals Inc.
Publication of SI2331098T1 publication Critical patent/SI2331098T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200931877T 2008-09-10 2009-09-10 Postopki za dajanje iloperidona SI2331098T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/208,027 US20100063093A1 (en) 2007-03-28 2008-09-10 Methods for the administration of iloperidone
EP09792421.1A EP2331098B1 (en) 2008-09-10 2009-09-10 Methods for the administration of iloperidone
PCT/US2009/056517 WO2010030783A1 (en) 2008-09-10 2009-09-10 Methods for the administration of iloperidone

Publications (1)

Publication Number Publication Date
SI2331098T1 true SI2331098T1 (sl) 2018-10-30

Family

ID=41280442

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931877T SI2331098T1 (sl) 2008-09-10 2009-09-10 Postopki za dajanje iloperidona

Country Status (8)

Country Link
US (5) US20100063093A1 (enExample)
EP (2) EP2331098B1 (enExample)
JP (1) JP2012502105A (enExample)
AU (1) AU2009291717A1 (enExample)
CA (1) CA2736245C (enExample)
ES (1) ES2688476T3 (enExample)
SI (1) SI2331098T1 (enExample)
WO (1) WO2010030783A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
CA3113166A1 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
KR20170008327A (ko) * 2012-03-14 2017-01-23 반다 파마슈티칼즈, 인코퍼레이티드. 정신적 질환의 치료 용도를 위한 일로페리돈 대사물질
CN116211857A (zh) 2015-02-17 2023-06-06 万达制药公司 用于治疗精神分裂症的伊潘立酮
US11214827B2 (en) * 2018-08-30 2022-01-04 Vanda Pharmaceuticals Inc. Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5130238A (en) * 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
GB9001181D0 (en) * 1990-01-18 1990-03-21 Imp Cancer Res Tech Genetic assay
US5846717A (en) * 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
WO2000055624A2 (en) 1999-03-15 2000-09-21 Leyland Jones Brian Elisa kit for the determination of metabolic phenotypes
IL145451A0 (en) * 1999-04-07 2002-06-30 Pfizer Prod Inc Use of cyp2d6 inhibitors in combination therapies
US20010034023A1 (en) * 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US7250252B2 (en) 1999-12-30 2007-07-31 David Aaron Katz Amplification based polymorphism detection
EP1290220B1 (en) * 2000-04-13 2007-12-19 Georgetown University Genetic diagnosis of qt prolongations as adverse drug reactions
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
AU2001275475A1 (en) * 2000-06-12 2001-12-24 Genicon Sciences Corporation Assay for genetic polymorphisms using scattered light detectable labels
US20020022254A1 (en) 2000-07-28 2002-02-21 Karl Guegler Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
WO2002044994A2 (en) 2000-11-30 2002-06-06 Third Wave Technologies, Inc. Systems and methods for detection assay ordering, design, production, inventory, sales and analysis for use with or in a production facility
GB0102841D0 (en) 2001-02-05 2001-03-21 Novartis Ag Organic compounds
WO2002073196A2 (en) * 2001-03-14 2002-09-19 Mcgill University Individualization of therapy with antipsychotics
EP1339879A4 (en) 2001-06-05 2004-12-29 Genaissance Pharmaceuticals METHOD OF IDENTIFYING POLYMORPHISM IN CYP2D6
WO2004009760A2 (en) 2002-07-18 2004-01-29 Bioventures, Inc. Cytochrome p450 genetic variations
US7195877B2 (en) * 2001-07-20 2007-03-27 Bioventures, Inc. Cytochrome P450 genetic variations
EP1281755A3 (en) * 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
JP2005525292A (ja) 2001-08-24 2005-08-25 アリックス セラピューティクス 非酸化的に代謝される化合物および組成物、それらの合成経路、ならびに使用方法
ES2370634T3 (es) * 2001-08-31 2011-12-21 Novartis Ag Isómeros ópticos de un metabolito de iloperidona.
CA2463158C (en) * 2001-10-30 2013-07-30 Novartis Ag Depot formulations of iloperidone and a star polymer
JP2005507261A (ja) 2001-10-31 2005-03-17 ノバルティス アクチエンゲゼルシャフト Ｔｃｆ１遺伝子における多型に基づく糖尿病および関連状態の治療方法
ATE503845T1 (de) 2001-12-10 2011-04-15 Novartis Pharma Gmbh Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen
US20040096874A1 (en) * 2002-04-11 2004-05-20 Third Wave Technologies, Inc. Characterization of CYP 2D6 genotypes
US20040091909A1 (en) * 2002-07-05 2004-05-13 Huang Doug Hui High throughput cytochrome P450 genotyping
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US8401801B2 (en) 2003-02-20 2013-03-19 Mayo Foundation For Medical Education And Research Methods for selecting medications
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050032070A1 (en) * 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
US20080166357A1 (en) * 2004-05-11 2008-07-10 Stefan Golz Diagnostics and Therapeutics for Diseases Associated with Dipeptidyl-Peptidase 6 (Dpp6)
CA3113166A1 (en) * 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
US20150259747A1 (en) 2007-03-29 2015-09-17 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
JP5586094B2 (ja) * 2007-03-29 2014-09-10 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｑｔ延長に対する素因を予測する方法
EP3075865B1 (en) 2007-05-18 2018-05-09 Vanda Pharmaceuticals Inc. Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
WO2009036056A1 (en) 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on snp genotype
JP5653753B2 (ja) 2007-09-10 2015-01-14 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｓｎｐ遺伝子型に基づくｑｔ延長の予測
CA2757723C (en) 2009-04-06 2018-07-24 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
EP3354753B1 (en) 2009-04-06 2020-02-12 Vanda Pharmaceuticals Inc. Method of treatment based on polymorphisms of the kcnq1 gene
JP5881597B2 (ja) 2009-04-06 2016-03-09 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｑｔ延長に対する素因を予測する方法
EP2416779B1 (en) 2009-04-06 2016-03-09 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof
WO2010132866A1 (en) 2009-05-15 2010-11-18 Vanda Pharmaceuticals Inc. Antipsychotic treatment based on drd2 or ankk1 snp genotype
KR20170008327A (ko) 2012-03-14 2017-01-23 반다 파마슈티칼즈, 인코퍼레이티드. 정신적 질환의 치료 용도를 위한 일로페리돈 대사물질
US11071728B2 (en) 2015-12-11 2021-07-27 Vanda Pharmaceuticals Inc. Treatment of schizophrenia
US11214827B2 (en) 2018-08-30 2022-01-04 Vanda Pharmaceuticals Inc. Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia

Also Published As

Publication number Publication date
AU2009291717A1 (en) 2010-03-18
EP2331098A1 (en) 2011-06-15
US20220259660A1 (en) 2022-08-18
CA2736245A1 (en) 2010-03-18
US20100063093A1 (en) 2010-03-11
EP3492081A1 (en) 2019-06-05
US20140039008A1 (en) 2014-02-06
ES2688476T3 (es) 2018-11-02
EP2331098B1 (en) 2018-08-08
WO2010030783A1 (en) 2010-03-18
JP2012502105A (ja) 2012-01-26
US20160053324A1 (en) 2016-02-25
US20190360047A1 (en) 2019-11-28
US12606869B2 (en) 2026-04-21
CA2736245C (en) 2022-07-12

Similar Documents

Publication Publication Date Title
IL212244A0 (en) Nicotine immunonatherapeutics
ZA201006252B (en) Preparation of lenalidomide
EP2379039A4 (en) SUPPORT FOR PATIENT
PL2245037T3 (pl) Nowe związki i sposoby leczenia
GB0811304D0 (en) Therapeutic agents
GB0813740D0 (en) Therapeutic compounds
GB0806794D0 (en) Therapeutic compounds
GB0804755D0 (en) Therapeutic compounds
IL213351A0 (en) Methods for the preparation of fungicides
SI2151428T1 (sl) Postopek za pripravo agomelatina
IL210393A0 (en) Administration regime for nitrocatechols
EP2212251A4 (en) PROCESS FOR THE PRODUCTION OF CLUSTERBOR
EG26332A (en) Process for the preparation of benzonoprons
GB0803054D0 (en) Medicament
GB0815788D0 (en) Therapeutic antibodies
SI2151429T1 (sl) Postopek za pripravo agomelatina
ZA201008860B (en) Pharmacokinetics of iontophorectic sumatriptan administration
ZA201000802B (en) Process for the preparation of alfuzosin hydrochloride
EP2324059A4 (en) THERAPEUTIC ANTI-PAMP ANTIBODIES
EP2205524A4 (en) METHODS OF MANUFACTURING CLUSTER BORON
EP2205525A4 (en) PROCESS FOR THE PREPARATION OF CLUSTERBORON
EP2173695A4 (en) PROCESS FOR THE PREPARATION OF CIS-4-TERT.-BUTYLCYCLOHEXANOL
IL219860A0 (en) Oral formulation for dexlansoprazole
IL211382A0 (en) Process for the preparation of ethanedinitrile
IL213560A0 (en) Enema formulations